Q1 Earnings Forecast for MRSN Issued By Leerink Partnrs

Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Mersana Therapeutics in a note issued to investors on Monday, March 3rd. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for Mersana Therapeutics' current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics' Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.15) EPS and Q4 2025 earnings at ($0.14) EPS.

A number of other brokerages have also recently commented on MRSN. William Blair started coverage on shares of Mersana Therapeutics in a research note on Thursday, February 6th. They set an "outperform" rating on the stock. Wedbush restated an "outperform" rating and set a $4.00 price target on shares of Mersana Therapeutics in a research report on Monday. Finally, Citigroup started coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They issued a "buy" rating and a $5.00 price objective for the company. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $4.25.

Mersana Therapeutics Stock Performance

MRSN stock traded up $0.02 during trading on Tuesday, hitting $0.54. 1,898,592 shares of the company traded hands, compared to its average volume of 2,373,484. Mersana Therapeutics has a 1 year low of $0.46 and a 1 year high of $6.28. The company has a market cap of $67.24 million, a PE ratio of -0.89 and a beta of 1.39. The stock's 50-day simple moving average is $0.75 and its 200 day simple moving average is $1.54. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.

Remove Ads

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business had revenue of $16.36 million during the quarter, compared to analyst estimates of $7.71 million.

Institutional Investors Weigh In On Mersana Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRSN. Novo Holdings A S acquired a new stake in shares of Mersana Therapeutics in the fourth quarter valued at about $6,078,000. Rock Springs Capital Management LP lifted its stake in Mersana Therapeutics by 12.6% in the 4th quarter. Rock Springs Capital Management LP now owns 3,431,684 shares of the company's stock valued at $4,907,000 after buying an additional 384,902 shares in the last quarter. State Street Corp boosted its holdings in Mersana Therapeutics by 1.6% in the 3rd quarter. State Street Corp now owns 2,725,394 shares of the company's stock worth $5,151,000 after buying an additional 43,339 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in Mersana Therapeutics during the 4th quarter worth approximately $3,768,000. Finally, Geode Capital Management LLC increased its stake in Mersana Therapeutics by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 2,442,250 shares of the company's stock worth $3,493,000 after buying an additional 29,035 shares in the last quarter. Hedge funds and other institutional investors own 93.92% of the company's stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.